Think Bioscience Raises $17M in Oversubscribed Seed Round to Develop Small Molecule Drugs that Hit Undruggable Proteins
Summary
Think is a spin-out from CU Boulder and is a client company of Innosphere Ventures incubation program.Nature endows living systems with the biochemical machinery to build an enormous variety of bioactive molecules. The company is focused on a several therapeutic areas, including oncology, autoimmune, and metabolic disease.Our proprietary technology leverages synthetic biology to build novel bioactive compounds, said Dr. Jerome Fox, cofounder and CEO at Think Bioscience. Think Biosciences approach encodes microbes with a drug design challenge and uses them to come up with new solutions, for example, novel inhibitors of a disease relevant enzyme.Xora Innovation, an early-stage deep tech investing platform of Temasek, has reinvested to co-lead this round. The firms central investment thesis, the Super Evolution, combines data, leading-edge computation, and advanced engineering to transform a range of industries, including agriculture, supply chain, the life sciences, transportation, and more. Its investments include AlphaSense, Astra, Color, Blue River Technology, Eikon Therapeutics, Fabric, Formlabs, Freenome, Planet, Rebellion Defense, Replica, SoFi, Uber, Upstart, Vicarious Surgical, and more.